A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Accent Therapeutics
Novartis
Elicio Therapeutics
Revolution Medicines, Inc.
UTC Therapeutics Inc.
Corvus Pharmaceuticals, Inc.
MacroGenics
Abramson Cancer Center at Penn Medicine
Washington University School of Medicine
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Cancer Research UK
National Cancer Institute (NCI)
NYU Langone Health